\
&
Contact us
\
&
Contact us
Published on | 9 months ago
Programmes Horizon Europe Digital EuropeIn 2025, the European Commission will put forward a comprehensive proposal for its next long-term budget – the multi-annual financial framework (MFF). The MFF is the European Commission’s long-term plan that sets out how much money the EU can spend over a period of seven years and on what areas. This includes EU funding for research and innovation.
The Commission believes that EU funding aimed at boosting competitiveness is divided across too many overlapping programmes, many of which support the same objectives but with varying requirements, making it difficult to combine funding effectively, thus limiting access to EU funds and reducing their overall impact.
As highlighted in President von der Leyen's Commission’s Political Guidelines, as well as in the Competitiveness Compass, the Commission will work on a simpler, more focused and impactful MFF that reflects the European strategic priorities with the ambition of being an investment-focused Commission.
A public consultation recently launched is part of the process. It contains questions about the challenges linked to competitiveness, the stage of technology that is important according to respondents and to what extent the current EU budget contributes to address certain challenges. The Commission also polls the measures that seem most impactful.
You can access the public consultation here. The deadline to provide your feedback is 6 May 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
